Company intelligence / Profile preview

Orexo AB

Ownership: Public · ORX
Employees: ~110
Development stage: Commercial

Overview

Orexo has successfully completed the pivotal trial for OX124, its lead pharmaceutical pipeline asset designed to reverse opioid overdoses. The study met its primary endpoints with naloxone exposure within the targeted interval, showing significantly faster and higher absorption compared to intramuscular dosing with the injection reference product[6]. The company planned to file a New Drug Application with the FDA in H2 2022[6], but received a Complete Response Letter from FDA in July 2024 requiring additional data, with plans to submit complementary data mid-2025[8].

Therapeutic areas: PsychiatryImmunologyWomen's HealthOncologyNeurology
Modalities: Small moleculespotentially peptides and proteins
Industry: Biotech

Drug pipeline

12 assets

Zubsolv

Approved

11 more assets in the full pipeline.

Request access →

Partnerships

Accord Healthcare (EU commercialization of Zubsolv)GAIA (digital therapeutics)Abera (nasal powder vaccines)Sobi (feasibility study with AmorphOX)Gesynta Pharma AB (OX-MPI)

Financials

Market cap: $380.1M
Total revenue: $7M

Beyond the preview

Go deeper on Orexo AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orexo AB.

Explore the full profile